Healthcare [ 4/11 ] | Biotechnology [ 50/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 23 | 0.14 Increased by +187.50% | 0.17 Decreased by -17.65% |
| May 9, 23 | -0.17 Decreased by -21.43% | -0.18 Increased by +5.56% |
| Feb 7, 23 | -0.17 Decreased by -21.43% | -0.19 Increased by +10.53% |
| Nov 28, 22 | -0.18 Decreased by -20.00% | -0.16 Decreased by -12.50% |
| Aug 9, 22 | -0.16 Decreased by -14.29% | -0.15 Decreased by -6.67% |
| May 10, 22 | -0.14 Decreased by -16.67% | -0.17 Increased by +17.65% |
| Feb 9, 22 | -0.14 Decreased by -16.67% | -0.15 Increased by +6.67% |
| Nov 24, 21 | -0.15 Decreased by -50.00% | -0.15 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 0.00 Decreased by N/A% | -11.28 M Increased by +8.79% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -13.11 M Decreased by -25.57% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -12.97 M Decreased by -19.20% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -14.29 M Decreased by -21.95% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0.00 Decreased by N/A% | -12.37 M Decreased by -21.48% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0.00 Decreased by N/A% | -10.44 M Decreased by -27.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0.00 Decreased by N/A% | -10.88 M Decreased by -38.54% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 21 | 0.00 Decreased by N/A% | -11.72 M Decreased by -96.44% | Decreased by N/A% Decreased by N/A% |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.